MacroGenics, Inc. provided a clinical update on its Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate, reporting that the squamous cell carcinoma of the head and neck (SCCHN) cohort met its pre-specified response threshold in Stage 1 and is proceeding to Stage 2. As of July 8, 2026, 74 patients have been enrolled in the study, with no reported cases of dose-limiting toxicities like interstitial lung disease or ocular toxicity. MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer.
